Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2021-11-11 | 2021-10-27 |
| Drug Identification Number | 02244622 | 02244622 |
| Brand name | MILRINONE LACTATE INJECTION, USP | MILRINONE LACTATE INJECTION, USP |
| Common or Proper name | Milrinone Lactate Injection 1 mg/mL SD Vial 10 mL | Milrinone Lactate Injection 1 mg/mL SD Vial 10 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | MILRINONE | MILRINONE |
| Strength(s) | 1MG | 1MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10 mL | 10 mL |
| ATC code | C01CE | C01CE |
| ATC description | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-11-01 | 2021-11-01 |
| Actual start date | ||
| Estimated end date | 2021-11-10 | 2021-11-18 |
| Actual end date | 2021-11-10 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Milrinone Lactate Injection 1 mg/mL SD Vial 10 mL effective November 1, 2021 until November 18, 2021. Once product is released, it will be removed from allocation. Our Milrinone Lactate Injection 1 mg/mL SD Vial 20 mL will be available for substitution. Allocations will be increased to cover 100% of the 20mL demand plus 100% of the 10mL demand based on a 1:2 conversion ratio. For example, 1 vial of 20mL = 2 vials of 10mL. | |
| Health Canada comments |